tiprankstipranks
BioVersys AG (CH:BIOV)
:BIOV
Switzerland Market
BIOV
BioVersys AG
RESEARCH TOOLSreports
Want to see CH:BIOV full AI Analyst Report?

BioVersys AG (BIOV) Stock News & Sentiment

2 Followers
BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
Premium
Company Announcements
BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
22d ago
BIOV
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
Premium
Company Announcements
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
1M ago
BIOV
Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
Premium
Ratings
Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
1M ago
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
Premium
Company Announcements
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
1M ago
BIOV
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
Premium
Company Announcements
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
1M ago
BIOV
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
Premium
Ratings
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
1M ago
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
Premium
Company Announcements
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
1M ago
BIOV
More CH:BIOV News >

BIOV News on the Web

Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
TipRanks News
Bullish
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
TipRanks News
Bullish
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
TipRanks News
Bullish
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
TipRanks News
Bullish
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
TipRanks News
Neutral
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
TipRanks News
Neutral
BioVersys Strengthens Investor Outreach With New IR and Communications Head
TipRanks News
Neutral
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
CH:BIOV
Sector Average
Media Buzz
This Week3 articles
Weekly Average2.25 articles
News Sentiment
This Week100%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:BIOV’s Media Buzz Sentiment?
3 articles about CH:BIOV were published this week. In an average week, 2.25 articles are published.
    What is CH:BIOV’s weekly average amount of articles?
    In an average week, 2.25 articles about CH:BIOV are published.
      What is CH:BIOV’s News Sentiment?
      100% of articles about CH:BIOV were positive this week, compared to its sector average of 79%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        JUNSJupiter Neurosciences, Inc.
        Showing the stocks with the most bullish news sentiment over the past week